New hope for hard-to-treat prostate cancer: targeted drug enters phase 2 trial
NCT ID NCT07111507
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a drug called tarlatamab in people with a specific type of advanced prostate cancer (DLL3-positive) that has spread and either came back or didn't respond to prior treatments. About 32 participants will receive the drug to see if it can shrink tumors or slow the cancer's growth. The goal is to find a new option for this difficult-to-treat cancer.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-••••
Locations
-
Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)
RECRUITINGBasking Ridge, New Jersey, 07920, United States
Contact Phone: •••-•••-••••
-
Memorial Sloan Kettering Bergen (Limited Protocol Activities)
RECRUITINGMontvale, New Jersey, 07645, United States
Contact Phone: •••-•••-••••
-
Memorial Sloan Kettering Cancer Center (All Protocol Activities)
RECRUITINGNew York, New York, 10065, United States
Contact Phone: •••-•••-••••
-
Memorial Sloan Kettering Monmouth (Limited Protocol Activities)
RECRUITINGMiddletown, New Jersey, 07748, United States
Contact Phone: •••-•••-••••
-
Memorial Sloan Kettering Nassau (Limited Protocol Activities)
RECRUITINGUniondale, New York, 11553, United States
Contact Phone: •••-•••-••••
-
Memorial Sloan Kettering Suffolk - Commack (Limited Protocol Activities)
RECRUITINGCommack, New York, 11725, United States
Contact Phone: •••-•••-••••
-
Memorial Sloan Kettering Westchester (Limited Protocol Activities)
RECRUITINGHarrison, New York, 10604, United States
Contact Phone: •••-•••-••••
-
Thomas Jefferson University Hospital
RECRUITINGPhiladelphia, Pennsylvania, 19107, United States
Contact Phone: •••-•••-••••
-
UNIVERSITY OF CALIFORNIA SAN DIEGO (Data collection only)
RECRUITINGSan Diego, California, 92103, United States
Contact Phone: •••-•••-••••
-
University of California San Francisco
RECRUITINGSan Francisco, California, 94143, United States
Contact Phone: •••-•••-••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a blast of testosterone shrink hard-to-treat prostate cancer?
- A PET scan and a blood test may predict which men with advanced prostate cancer will benefit from targeted therapy
- New drug ORIC-944 targets Hard-to-Treat prostate cancer
- Precision radiotherapy may buy time for men with spreading prostate cancer
- Mapping Cancer's next move: study tracks where prostate cancer returns after aggressive radiotherapy
- Smart scans may slash radiation doses for metastatic prostate cancer